Methods for treating NETosis and neutrophil activation
AssigneeTrustees of Boston University
InventorsNelson Ruiz-Opazo, Victoria L.M. Herrera
Life of this patent
Estimating the term…
Abstract
Described herein are methods and compositions relating to methods of inhibiting neutrophils, e.g., inhibiting NET release or NETosis, by means of a DEspR inhibitor, e.g., an anti-DEspR antibody reagent. In some embodiments, the methods can relate to the treatment of a disease, e.g., cancer or a disease wherein neutrophils; NETs; or NETosing or NETting neutrophils contribute to pathogenesis, chronicity, or worsening of disease. In some embodiments, the DEspR inhibitor can be a bi-specific reagent or an antibody-drug conjugate.
Claims19
A method of preventing or decreasing neutrophil extracellular trap (NET) levels or release in a subject determined to have an increased level of NETs as indicated by the presence of Dual Endothelin/VEGF Signal Peptide Receptor (DEspR)+neutrophils or NET-forming neutrophils, as compared to a healthy subject, the method comprising administering a therapeutically effective amount of an anti-DEspR antibody reagent to the subject;
- wherein the therapeutically effective amount of an anti-DEspR antibody reagent does not bind to or cause neutropenia of quiescent neutrophils or CD11b+neutrophils that do not express DEspR.
A method of decreasing or treating tissue injury exacerbated or caused by neutrophil extracellular trap (NET) levels or release in a subject in need thereof, the method comprising administering a therapeutically effective amount of an anti-DEspR antibody to a subject;
- whereby the NET levels or release are reduced;
- wherein the therapeutically effective amount of an anti-DEspR antibody reagent does not bind to or cause neutropenia of quiescent neutrophils or CD11b+neutrophils that do not express DEspR.
Dependencies are inferred from the claim text.